Results 131 to 140 of about 67,119 (304)

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

Journal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel, Tse Wen Chang, Carmay Lim   +2 more
wiley   +1 more source

Immunomodulatory effects of CD38-targeting antibodies

, 2018
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma.
van de Donk, Niels W. C. J.
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Molecular characterization of novel ADP-ribosyl cyclases from the sea urchin

, 2010
Calcium signalling is ubiquitous and regulates diverse cellular processes. Cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) are second messengers that are involved in calcium release from the intracellular organelles ...
Ramakrishnan, L.
core  

Immuno-targeting the multifunctional CD38 using nanobody

, 2016
CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease.
Zhang, Peng, Hou, Yun Nan, Lam, Connie M. C., Lee, Hon Cheung, Deng, Qi Wen, Unger, Mandy, Qi, Shali, Xin, Du, Wang, Xian Wang, Zhao, Yong Juan, Zhang, Hongmin, Li, Ting, Hao, Quan, Liu, Jun, Koch-Nolte, Friedrich   +14 more
core   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Tp53 Genetic Mutations in Chronic Lymphocytic Leukemia Patients in Iraq

Journal of Applied Hematology
Background: Chronic lymphocytic leukemia (CLL) is a malignant clonal proliferative condition of mature CD5+ B cells, with a 4.2/100,000 annual incidence rate and the median age at diagnosis is 72 years.
Kareem Abed Mobashr, Liqaa Mohammed Al Sharifi, Afraa Mahdi Jawad   +2 more
doaj   +1 more source

Structure and Enzymatic Functions of Human CD38

Molecular Medicine, 2006
CD38 is a novel multifunctional protein that serves not only as an antigen but also as an enzyme. It catalyzes the metabolism of cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate, two structurally and functionally distinct Ca(2+) messengers targeting, respectively, the endoplasmic reticulum and lysosomal Ca(2+) stores. The protein has
openaire   +4 more sources